- Home
- ABSI vs XERS Comparison
ABSI vs XERS Comparison
Compare ABSI & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ABSI | XERS |
|---|---|---|
| Founded | 2011 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 997.8M | 1.0B |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ABSI | XERS |
|---|---|---|
| Price | $6.53 | $7.07 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 6 |
| Target Price | $6.96 | ★ $10.83 |
| AVG Volume (30 Days) | ★ 4.5M | 1.4M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 10.64 | ★ 100.00 |
| EPS | N/A | ★ 0.01 |
| Revenue | $4,534,000.00 | ★ $49,590,000.00 |
| Revenue This Year | $215.96 | $34.37 |
| Revenue Next Year | $319.10 | $22.86 |
| P/E Ratio | ★ N/A | $693.00 |
| Revenue Growth | N/A | ★ 142.67 |
| 52 Week Low | $2.24 | $4.36 |
| 52 Week High | $7.39 | $10.08 |
Technical Indicators
Market Signals| Indicator | ABSI | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 57.46 | 69.15 |
| Support Level | $2.55 | $6.86 |
| Resistance Level | $7.06 | $7.14 |
| Average True Range (ATR) | 0.68 | 0.23 |
| MACD | -0.00 | 0.09 |
| Stochastic Oscillator | 62.05 | 98.43 |
Price Performance
Historical ComparisonAbout ABSI Absci Corporation
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process. Its lead product candidate, ABS-201, is an anti-prolactin receptor (PRLR) antibody engineered with an extended half-life to support a patient-friendly dosing interval.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.